RecruitingNCT04935853

Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Enrollment

1,350 participants

Start Date

May 23, 2022

Study Type

OBSERVATIONAL

Conditions

Biliary Tract Cancer

Summary

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study collects clinical data and tissue samples from patients with bile duct cancer (cholangiocarcinoma) and gallbladder cancer to identify markers that predict how patients respond to treatment. **You may be eligible if...** - You have been diagnosed with bile duct cancer (intrahepatic, extrahepatic) or gallbladder cancer - You are 18 or older - You were diagnosed between 2003 and 2030 - You are willing to have your data and tumor samples used for research **You may NOT be eligible if...** - You are under legal guardianship or curatorship - You are pregnant or breastfeeding - You refuse to participate - You have a significant medical or psychological condition that would prevent participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(32)

CHU Hôpital Sud Amiens

Amiens, France

CHU Angers

Angers, France

CHU Besançon

Besançon, France

Hôpital Avicenne

Bobigny, France

CHU - Henri Mondor

Créteil, France

CHU Dijon

Dijon, France

CHU Grenoble

Grenoble, France

CHU Lille

Lille, France

Centre Léon Bérard

Lyon, France

Hôpital Croix Rousse

Lyon, France

Hôpital Edouard Herriot

Lyon, France

Hôpital Privé Jean Mermoz

Lyon, France

Institut Paoli Calmette

Marseille, France

CHU Saint Eloi Montpellier

Montpellier, France

CHR Orléans

Orléans, France

Groupe Hospitalier Pitié Salpêtrière

Paris, France

Hôpital Ambroise Paré

Paris, France

Hôpital Cochin

Paris, France

Hôpital Saint Antoine

Paris, France

Hôpital Saint Louis

Paris, France

Institut Mutualiste Montsouris

Paris, France

Hôpital Haut Lévêque

Pessac, France

CHU Poitiers

Potiers, France

Hôpital Robert Debré -CHU Reims

Reims, France

Centre Eugène Marquis

Rennes, France

CHU Rouen Charles Nicolle

Rouen, France

Institut Curie

Saint-Cloud, France

CHU Saint Etienne

Saint-Etienne, France

CHU Rangueil

Toulouse, France

CHU Tours

Tours, France

CHRU Nancy Site Brabois

Vandœuvre-lès-Nancy, France

Institut Gustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04935853

Related Trials

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT062391946 locations

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

NCT0702106617 locations

Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

NCT075696791 location

Study for AZD4360 in Participants With Advanced Solid Tumours

NCT0692192818 locations

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT0577515960 locations